Identification of genetic causes of neutropenia informs precision medicine approaches to medical management and treatment. Accurate diagnosis of genetic neutropenia disorders informs treatment options, enables risk stratification, cancer surveillance, and attention to associated medical complications. The rapidly expanding genetic testing options for the evaluation of neutropenia have led to exciting advances but also new challenges. This review provides a practical guide to germline genetic testing for neutropenia.
| INTRODUCTION
Neutropenia, typically defined as an absolute neutrophil count <1500/μL, is a common cause of referral to both adult and pediatric hematologists. Although most cases of neutropenia are transient and extrinsic to the bone marrow, the diagnosis of an underlying genetic neutropenia disorder profoundly alters clinical management. Many of the genetic neutropenia disorders are associated with leukemia predisposition, or additional medical comorbidities (Table 1) . 61, 62 This review focuses on practical considerations for germline genetic testing of neutropenia, including which patients to test, which tests to send, and interpretation of results. The reader is referred to other excellent recent publications for a comprehensive review of genetic neutropenia disorders [63] [64] [65] or a review of the clinical evaluation and management of neutropenia disorders. [66] [67] [68] Accurate and early diagnosis of genetic neutropenias informs clinical care. Correct diagnosis allows for informed treatment decisions, initiation of surveillance strategies for patients at increased risk of leukemia, and for informed donor selection in the case of hematopoietic stem cell transplantation (HSCT) to avoid selecting an affected but clinically cryptic family member. Timely diagnosis of a genetic neutropenia disorder prior to the development of MDS or AML is essential since the long time-frame for genetic testing may preclude diagnosis for such patients who urgently require a HSCT. Families also benefit from genetic counseling for family planning, consideration of preimplantation genetic diagnosis to both test for the genetic neutropenia disorder and to match HLA type, and to discuss testing of additional family members. The identification of the genetic causes of congenital neutropenia advances our understanding of neutrophil biology and function which in turn provides the basis for new targeted therapies. 69 
| GENETIC TESTING: WHOM TO TEST?
Although many patients with a genetic neutropenia disorder present in childhood, some patients who are otherwise asymptomatic or have mild or moderate neutropenia with fluctuating counts present to medical care in adulthood with neutropenia, cytopenias, or a myeloid malignancy. Indeed, in a recent study of MDS, 4% of patients who required
HSCT were found to have compound heterozygous mutations in SBDS, of whom only 2 out of the 7 carried a clinical diagnosis of Shwachman Diamond syndrome (SDS). Notably, these patients were significantly younger than the average MDS patient in the cohort, highlighting their genetic predisposition to myeloid malignancy. 70 The reader is referred to excellent reviews on the general diagnostic evaluation of neutropenia. 66, 67, 71 whether to report an identified mutation and this differs between somatic and germline, as described in a genomic analysis of both germline and somatic variants in MDS and leukemia. 79 Therefore in many cases, multiplexed targeted analysis with nextgeneration sequencing panels for multiple neutropenia genes are generally cost effective and efficient especially considering the wide variability and overlap in clinical phenotypes. 63 However, the utility of any targeted gene panel is dependent on (1) the specific set of genes included, (2) the coverage of coding regions and pathogenic noncoding regions, and (3) the post-sequencing analysis.
| GENETIC TESTING PLATFORMS
For those patients for whom a genetic cause is not identified by the above methods, whole exome sequencing (WES) or whole genome sequencing (WGS) can be powerful tools. In WES, the exomes are sequenced using next generation sequencing techniques which can identify mutations in both protein-coding and non-coding-RNA genes. Identification of new, previously unrecognized genetic mutations via WES has increased our understanding of the pathogenesis of many disease types including recently SCN6 due to JAGN1 mutations. 15 However, it is necessary to note that some regions of • May be sent after an initial genetic evaluation returns negative but there is a strong suspicion of a germline mutation
• Will miss pathogenic noncoding regulatory regions (promoters and enhancers)
Whole genome sequencing • Typically done on a research basis if whole exome sequencing is negative
• Analysis is challenging
• Strong suspicion that a mutation may be in a region missed by whole exome sequencing in ELANE and roughly 40% of patients have a negative result on targeted gene panels. 63, 86, 87 The clinician must assess which genes have not been queried and determine whether to send additional testing.
| GENETIC TESTING: IMPLICATIONS FOR MANAGEMENT
The reader is referred to excellent reviews discussing the general management and treatment of neutropenia. 66, 67 Notably for this discussion, identification of a specific genetic cause of a patient's neutropenia may predict response to therapies such as G-CSF, and identify patients at risk of bone marrow failure and/or clonal evolution to MDS or AML which is information which otherwise would not have been available for the indi- this is likely to be a potential therapeutic option in the future. 4 
| FUTURE DIRECTIONS
Increasingly, powerful tools for genetic testing have spurred advances in the biology of hematopoiesis through the identification of previously unknown neutropenia genes. 90, 91 However, there is a paucity of data regarding the phenotypic spectrum and natural history of genetic neutropenias, 8 and neutropenia registries and consortia continue to be instrumental for the study of congenital neutropenia syndromes. 52, [92] [93] [94] Going forward, clinical utility of genetic testing and the ease of interpreting results will depend on the development of publicly accessible, regularly updated databases with expert annotation of genetic variants. TEST OF THE MONTH   NEUTROPENIA IN THE AGE OF GENETIC TESTING: ADVANCES AND CHALLENGES   SUMMARY TABLE: Who might benefit from genetic testing for neutropenia?
The following features should prompt consideration of genetic testing: When should testing be sent?
Early genetic evaluation prior to the development of clinical complications is recommended for those patients suspected of having a genetic neutropenia disorder to inform treatment decisions and medical management.
What is the role of genetic counseling?
Patients and families should receive counseling regarding the indications, risks, and limitations of genetic testing; the expected time frame for receiving results; and the potential impact on clinical decision-making. A joint discussion involving both a hematologist and a genetic counselor experienced with genetic neutropenia disorders is recommended.
What options are available for genetic testing?
1. Sanger sequencing of single gene can be cost-effective when suspicion for a specific gene is high, or when screening family members of a proband with a known mutation. What are the differences between somatic and germline panels?
Certain genes may be mutated constitutionally in the germline to cause neutropenia and also mutated somatically in hematopoietic cells such as in MDS or hematologic malignancies. Somatic testing panels for hematologic malignancies typically target specific regions that are mutated somatically and therefore may result in false negatives if they are sent in lieu of panels designed for germline hematologic disorders which may require sequencing of the entire gene, evaluation of known pathogenic non-coding regions, and evaluation for partial or whole gene deletions. Each testing panel also uses a different variant allele fraction threshold to determine whether to report an identified mutation and this differs between somatic and germline genetic panels.
What are the sample requirements for testing?
Although a blood sample for DNA extraction is typically used for genetic testing, hematopoietic cells may acquire somatic mutations (see above). Therefore, testing of a non-hematopoietic tissue such as skin fibroblasts may sometimes be required to distinguish germline versus somatic mutations.
What do I do with variants of unknown significance (VUS)?
Variants are more likely to be pathogenic if absent from control databases, conserved across orthologues, and have higher pathogenicity scores using in-silico models. Sequencing a trio (mother, father, and affected proband), and/or additional affected and unaffected family members can be helpful to determine whether the variant tracks with the clinical phenotype, though variable penetrance may confound the analysis. Variants can be functionally validated if a clinically relevant assay is available.
How might genetic testing affect clinical management?
Correct diagnosis allows for informed treatment decisions, initiation of surveillance strategies for patients at increased risk of leukemia, and for informed donor selection in the case of hematopoietic stem cell transplantation (HSCT) to avoid selecting an affected but clinically cryptic family member. Families also benefit from genetic counseling for family planning, consideration of preimplantation genetic diagnosis to both test for the genetic neutropenia disorder and to match HLA type, and allow counseling of any additional interested family members.
Consultation with an expert in genetic neutropenia disorders can be helpful to guide diagnostic genetic testing and interpretation of results.
